Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Sanofi launches 2023 global Employee Stock Purchase Plan  

Sanofi launches 2023 global Employee Stock Purchase PlanParis, June 1 2023. Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 coun... Read More
Sanofi
2 years ago ⋅ English ⋅ 5 min read
Newsroom
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis- Frexalimab met primary endpoin... Read More
Sanofi
2 years ago ⋅ English ⋅ 2 min read
Newsroom
Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors- Approval of the financial statements for the fiscal year 2022- Distribution of a cash div... Read More
Sanofi
2 years ago ⋅ English ⋅ 2 min read
Newsroom
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine- Dupixent is the first and only investigati... Read More
Sanofi
2 years ago ⋅ English ⋅ 1 min read
Newsroom
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting- HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy again... Read More
Sanofi
2 years ago ⋅ English ⋅ 1 min read
Newsroom
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting- HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy again... Read More